It has recently been reported that KRAS mutant can promote Rad51 expression to increase the chemotherapy resistance of cancer cells, while inhibiting HDAC can down-regulate Rad51 to counteract Rad51-mediated resistance of cancer cells [14, 15]. The gene discussed is KRAS; the disease is cancer.